Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Zenstral PMS** is an oral fixed-dose nutraceutical caplet developed initially by University Lab Technologies and subsequently promoted by University Health Industries for premenstrual syndrome. The product combines standardized *Vitex agnus-castus* extract, magnesium oxide, and pyridoxine. Its proposed activity is driven principally by chasteberry's dopaminergic and pituitary-related effects, while magnesium and vitamin B6 provide nutritional support relevant to neuromuscular and neurotransmitter function. Public promotional materials described it as a patent-pending supplement for relief of PMS-associated physical and cyclical mood symptoms, rather than as an approved pharmaceutical treatment. ([businesswire.com](https://www.businesswire.com/news/home/20080428005198/en/University-Health-Industries-Launches-National-Television-Commercial))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zenstral PMS.